The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1314
June 15, 2009
View Complete Issue         Table of Contents 2019 
Milnacipran (Savella) for Fibromyalgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Milnacipran (Savella) for Fibromyalgia
June 15, 2009 (Issue: 1314)
Milnacipran (Savella - Forest), an oral selective serotonin and norepinephrine reuptake inhibitor (SNRI), is the third drug approved by the FDA for management of fibromyalgia. The 2 others are pregabalin, a gammaaminobutyric acid (GABA) analog also...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Milnacipran (Savella) for Fibromyalgia
Article code: 1314b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.